The New Era of Long-Acting Antiretroviral Therapy: When and Why to Make the Switch
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The New Era of Long-Acting Antiretroviral Therapy: When and Why to Make the Switch
Authors
Keywords
-
Journal
Current HIV/AIDS Reports
Volume 20, Issue 5, Pages 271-285
Publisher
Springer Science and Business Media LLC
Online
2023-09-21
DOI
10.1007/s11904-023-00665-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection: 152-week results from ATLAS-2M, a randomized, open-label, Phase 3b, noninferiority study
- (2023) Edgar T Overton et al. CLINICAL INFECTIOUS DISEASES
- Long-acting injectable antiretroviral therapy: will it change the future of HIV treatment?
- (2023) Marisa Brizzi et al. Therapeutic Advances in Infectious Disease
- Long-acting antiretrovirals and HIV treatment adherence
- (2023) Jean B Nachega et al. Lancet HIV
- Equity in access to long-acting injectables in the USA
- (2022) J Carlo Hojilla et al. Lancet HIV
- Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection
- (2022) Sorana Segal-Maurer et al. NEW ENGLAND JOURNAL OF MEDICINE
- First Demonstration Project of Long-Acting Injectable Antiretroviral Therapy for Persons With and Without Detectable HIV Viremia in an Urban HIV Clinic
- (2022) Katerina A Christopoulos et al. CLINICAL INFECTIOUS DISEASES
- Compassionate use of long‐acting cabotegravir plus rilpivirine for people living with HIV ‐1 in need of parenteral antiretroviral therapy
- (2022) Ronald D'Amico et al. HIV MEDICINE
- Role of islatravir in HIV treatment and prevention: an update
- (2022) Abdallah Derbalah et al. Current Opinion in HIV and AIDS
- Perspectives of healthcare providers on implementation of long‐acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation‐effectiveness study (CUSTOMIZE)
- (2022) Maggie Czarnogorski et al. Journal of the International AIDS Society
- Early Experience Implementing Long-Acting Injectable Cabotegravir/Rilpivirine for Human Immunodeficiency Virus-1 Treatment at a Ryan White-Funded Clinic in the US South
- (2022) Lauren F Collins et al. Open Forum Infectious Diseases
- A Patient Decision Aid (i.ARTs) to Facilitate Women’s Choice Between Oral and Long-Acting Injectable Antiretroviral Treatment for HIV: Protocols for its Development and Randomized Controlled Pilot Trial
- (2022) Morgan M Philbin et al. JMIR Research Protocols
- Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of HIV in Low- and Middle-Income Countries (LMICs)
- (2022) Cissy Kityo et al. CLINICAL INFECTIOUS DISEASES
- Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of Human Immunodeficiency Virus (HIV) in High-Income Countries
- (2022) Stanley E Cooper et al. CLINICAL INFECTIOUS DISEASES
- What Clinicians Need to Know About the Development of Long-Acting Formulations
- (2022) Charles Flexner et al. CLINICAL INFECTIOUS DISEASES
- Long-Acting Treatments for Hepatitis B
- (2022) David L Thomas et al. CLINICAL INFECTIOUS DISEASES
- Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial
- (2022) Samir K Gupta et al. Lancet HIV
- 1584. CARISEL A Hybrid III Implementation Effectiveness Study of implementation of Cabotegravir plus Rilpivirine Long Acting (CAB+RPV LA) in EU Health Care Settings Key Clinical and Implementation Outcomes by Implementation Arm
- (2022) Stephane De Wit et al. Open Forum Infectious Diseases
- A Qualitative Exploration of Women's Interest in Long-Acting Injectable Antiretroviral Therapy Across Six Cities in the Women's Interagency HIV Study: Intersections with Current and Past Injectable Medication and Substance Use
- (2021) Morgan M. Philbin et al. AIDS PATIENT CARE AND STDS
- Risks and benefits of reducing the number of drugs to treat HIV-1 infection
- (2021) Julen Cadiñanos et al. Expert Opinion On Drug Safety
- Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study
- (2021) Ben Parker et al. PLoS One
- Factors associated with interest in a long-acting HIV regimen: perspectives of people living with HIV and healthcare providers in four European countries
- (2021) Babatunde Akinwunmi et al. SEXUALLY TRANSMITTED INFECTIONS
- Predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine
- (2021) Amy G. Cutrell et al. AIDS
- Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials
- (2021) Andrea Mantsios et al. BMC HEALTH SERVICES RESEARCH
- Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
- (2021) Daryl Hodge et al. CLINICAL PHARMACOKINETICS
- The potential role of long-acting injectable cabotegravir–rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis
- (2021) Andrew N Phillips et al. Lancet Global Health
- Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study
- (2021) Chloe Orkin et al. Lancet HIV
- Long-acting cabotegravir + rilpivirine for HIV-1 treatment
- (2021) Susan Swindells et al. AIDS
- Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
- (2021) Hans Jaeger et al. Lancet HIV
- Antiretroviral therapy experience, satisfaction, and preferences among a diverse sample of young adults living with HIV
- (2021) Chadwick K. Campbell et al. AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV
- A multi-site study of women living with HIV’s perceived barriers to, and interest in, long-acting injectable anti-retroviral therapy
- (2020) Morgan M. Philbin et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
- (2020) Chloe Orkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
- (2020) Susan Swindells et al. NEW ENGLAND JOURNAL OF MEDICINE
- Weight gain among treatment‐naïve persons with HIV starting integrase inhibitors compared to non‐nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada
- (2020) Kassem Bourgi et al. Journal of the International AIDS Society
- “A dream come true”: Perspectives on long-acting injectable antiretroviral therapy among female sex workers living with HIV from the Dominican Republic and Tanzania
- (2020) Deanna Kerrigan et al. PLoS One
- Reasons People Living with HIV Might Prefer Oral Daily Antiretroviral Therapy, Long-Acting Formulations, or Future HIV Remission Options
- (2020) Karine Dubé et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy
- (2020) Giuliano Rizzardini et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- The LAIs Are Coming! Implementation Science Considerations for Long-Acting Injectable Antiretroviral Therapy in the United States: A Scoping Review
- (2020) John T. Kanazawa et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Long-acting drugs and formulations for the treatment and prevention of HIV infection
- (2020) Charles Flexner et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
- (2020) Edgar T Overton et al. LANCET
- Understanding HIV-Related Pill Aversion as a Distinct Barrier to Medication Adherence
- (2019) Robin M. Dorman et al. BEHAVIORAL MEDICINE
- Long-Acting Injectable Antiretroviral Treatment Acceptability and Preferences: A Qualitative Study Among US Providers, Adults Living with HIV, and Parents of Youth Living with HIV
- (2019) Jane M. Simoni et al. AIDS PATIENT CARE AND STDS
- Greater Weight Gain in Treatment Naïve Persons Starting Dolutegravir-Based Antiretroviral Therapy
- (2019) Kassem Bourgi et al. CLINICAL INFECTIOUS DISEASES
- Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials
- (2019) Paul E Sax et al. CLINICAL INFECTIOUS DISEASES
- Prevalence and burden of HBV co‐infection among people living with HIV: A global systematic review and meta‐analysis
- (2019) Lucy Platt et al. JOURNAL OF VIRAL HEPATITIS
- Reorienting health systems to care for people with HIV beyond viral suppression
- (2019) Kelly Safreed-Harmon et al. Lancet HIV
- Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies
- (2018) Josep M Llibre et al. LANCET
- Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain
- (2018) Deanna Kerrigan et al. PLoS One
- Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir
- (2018) Maureen Oliveira et al. Retrovirology
- Interest of Youth Living with HIV in Long-Acting Antiretrovirals
- (2018) Ethel D. Weld et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Patient-Reported Barriers to Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis
- (2016) Zara Shubber et al. PLOS MEDICINE
- Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
- (2015) Paul E Sax et al. LANCET
- Formulation and pharmacology of long-acting cabotegravir
- (2015) Christine Trezza et al. Current Opinion in HIV and AIDS
- Association of tenofovir exposure with kidney disease risk in HIV infection
- (2012) Rebecca Scherzer et al. AIDS
- TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1
- (2009) H. Azijn et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started